Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2157299 with Neoadjuvant Chemoradiation in Rectal Adenocarcinoma
NCT02688712Phase 2Active, not recruiting
- Start
- Mar 2016
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of galunisertib in rectal adenocarcinoma. Started Mar 2016; status: active, not recruiting.
02
Drugs
galunisertib
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02688712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688712.